Original article
Tumour marker detection in oesophageal carcinoma

https://doi.org/10.1016/S0748-7983(96)92998-4Get rights and content

Levels of the tumour markers CEA, CA 19-9, CA 125 and SCC were measured in 58 patients presenting with oesophageal carcinoma and compared with levels in patients with benign oesophageal disease and levels in normal volunteers. CEA and CA 19-9 were significantly increased in the patients with oesophageal cancer, however, individual sensitivity for CEA, CA 19-9, CA 125 and SCC was only 28, 34, 10, and 32%, respectively. The combined sensitivity of all markers was 64% and specificity was 80%. There was no difference in combined tumour marker sensitivity between squamous or adenocarcinomas of the oesophagus. No consistent change in marker levels occurred with treatment, and tumour marker levels could not be significantly correlated with stage of disease or short-term survival. These results indicate that tumour marker sensitivity is too low for oesophageal cancer screening and has poor prognostic significance in those undergoing treatment.

References (9)

  • PeraM et al.

    Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction

    Gastroenterology

    (1993)
  • HebermanR

    Principles of tumor immunology

  • JalankoH et al.

    Comparison of new tumour marker, CA 19-9™, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases

    J Clin Path

    (1984)
  • WobblesT et al.

    Evaluation of seven tumour markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, Carcinoembryonic Antigen and Tissue Polypeptide Antigen) in the pretreatment of patients with gastric carcinoma

    Cancer

    (1992)
There are more references available in the full text version of this article.

Cited by (0)

View full text
Copyright © 1996 Published by Elsevier Ltd.